Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 8
Submit an article Journal homepage
301
Views
16
CrossRef citations to date
0
Altmetric
Drug Profile

Bevacizumab for the treatment of glioblastoma

Sajeel Chowdhary; Florida Hospital Cancer Institute, Orlando, FL, USA; Florida Hospital Neuroscience Institute, Orlando, FL, USA; Walt Disney Pavilion, Florida Hospital for Children, Orlando, FL, USA; Department of Neuro-Oncology, University of Central Florida, Orlando, FL, USA
&
Marc Chamberlain; Department of Neurology, University of Washington, 825 Eastlake Ave E, Mail Stop: G4-940, Seattle, WA 98109-1023, USA. [email protected]; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Seattle Cancer Care Alliance, Seattle, WA, USA
Pages 937-949 | Published online: 09 Jan 2014

References

  • Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733–4740 (2009).
  • Cloughesy T, Vredenburgh JJ, Day B et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J. Clin. Oncol. 28(15 Suppl.), Abstract 2008 (2010).
  • Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13, 1253–1259 (2007).
  • Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722–4729 (2007).
  • Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740–745 (2009).
  • Quant E, Norden AD, Drappatz J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen. J. Clin. Oncol. 26(15 Suppl.) (2008).
  • Zuniga RM, Torcuator R, Jain R et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol. 99(2), 237–242 (2010).
  • Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J. Clin. Oncol. 26(6), 1012–1013 (2008).
  • Gilbert MR, Wang MH, Aldape KD et al. RTOG 0525: A randomized Phase III trial comparing standard adjuvant temozolomide (TMZ) with dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). Neuro-Oncol. 13(Suppl. 3), Abstract 46 (2011).
  • Stupp R, Dietrich PY, Ostermann KS et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20, 1375–1382 (2002).
  • Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26(13), 2192–2197 (2008).
  • Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
  • Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
  • Westphal M, Ram Z, Riddle V, Hilt D, Bortey E; Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir. (Wien) 148(3), 269–275; discussion 275 (2006).
  • Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol. 5, 79–88 (2003).
  • Vauleon E, Mesbah H, Gedouin D et al. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab]. Bull. Cancer 99, 121–126 (2012).
  • Spiegel BM, Esrailian E, Laine L, Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 21, 775–787 (2007).
  • Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncol. 7, 369, Abstract 342 (2005).
  • Chinnaiyan P, Chowdhary S, Potthast L et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro-Oncol. 14(1), 93–100 (2012).
  • Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492–507 (2008).
  • Lamborn KR, Yung WK, Chang SM et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncol. 10, 162–170 (2008).
  • Sathornsumetee S, Rich JN. Molecularly targeted therapy in neuro-oncology. Handb. Clin. Neurol. 104, 255–278 (2012).
  • de Groot JF. High-dose antiangiogenic therapy for glioblastoma: less may be more? Clin. Cancer Res. 17(19), 6109–6111 (2011).
  • Shirai K, Siedow MR, Chakravarti A. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J. Oncol. 2012, 193436 (2012).
  • Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin. Ther. Targets 13, 455–468 (2009).
  • Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182–1186 (1971).
  • Risau W. Mechanisms of angiogenesis. Nature 386(6626), 671–674 (1997).
  • Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438(7070), 932–936 (2005).
  • Fidler IJ, Ellis LM. Neoplastic angiogenesis – not all blood vessels are created equal. N. Engl. J. Med. 351(3), 215–216 (2004).
  • Los M, Voest EE. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin. Oncol. 28(1), 93–105 (2001).
  • Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69(Suppl. 3), 11–16 (2005).
  • Brem S, Cotran R, Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J. Natl Cancer Inst. 48, 347–356 (1972).
  • Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat. Rev. Neurosci. 8, 610–622 (2007).
  • Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69–82 (2007).
  • Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
  • Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539–1544 (2007).
  • Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542–2550 (2006).
  • Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).
  • Rohr UP, Augustus S, Lasserre SF, Compton P, Huang J. Safety of bevacizumab in patients with metastases to the central nervous system. J. Clin. Oncol. 27(15 Suppl.), Abstract 2007 (2009).
  • Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncol. 7, 134–153 (2005).
  • Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731–3736 (2004).
  • Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
  • Reardon DA, Desjardins A, Peters KB et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J. Neurooncol. 107, 155–164 (2011).
  • Desjardins A, Reardon DA, Coan A et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118, 1302–1312 (2011).
  • Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin. Med. Insights Oncol. 5, 117–129 (2011).
  • Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. J. Clin. Oncol. 27(15 Suppl.), Abstract 2045 (2009).
  • Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70, 779–787 (2008).
  • Gilbert MR, Wang M, Aldape K et al. RTOG 0625: A Phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J. Clin Oncol. 27(15 Suppl.), Abstract 2011 (2009).
  • Desjardins A, Reardon DA, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin. Cancer Res. 14, 7068–7073 (2008).
  • Rademaker AW, Renfrow J, Bredel M. A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22), 5297–5305 (2010).
  • De Fazio S, Russo E, Ammendola M, Di Paola ED, De Sarro G. Efficacy and safety of bevacizumab in glioblastomas. Curr. Med. Chem. 19, 972–981 (2012).
  • Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91, 329–336 (2009).
  • Hapani S, Wu S. Controversial role of bevacizumab in the development of venous thromboembolic events. J. Clin. Oncol. 29(25), 3490; author reply 3490–3491 (2011).
  • Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro-Oncol. doi:10.1093/neuonc/nor223 (2012).
  • Vogelbaum MA, Jost S, Aghi MK et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 70(1), 234–243; discussion 243–244 (2012).
  • Raizer JJ, Grimm S, Chamberlain MC et al. A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22), 5297–5305 (2010).
  • Selfridge JM. Timing of bevacizumab in recurrent glioblastoma. SNO Annual Scientific Meeting Washington DC, USA November 2012.
  • Clark AJ, Butowski NA, Chang SM et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J. Neurosurg. 114(6), 1609–1616 (2011).
  • Norden AD, Bartolomeo J, Tanaka S et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J. Neurooncol. 106(1), 121–125 (2012).
  • Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142–148 (2011).
  • Narayana A, Gruber D, Kunnakkat S et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J. Neurosurg. 116(2), 341–345 (2011).
  • Vredenburgh JJ, Desjardins A, Reardon DA et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin. Cancer Res. 17(12), 4119–4124 (2011).
  • Chinot OL. AVAglio preliminary data presentation. SNO Annual Scientific Meeting 2012. Preliminary AVAglio data presented by Chinot revealing a significant increase in PFS so far in the arm that received BEV plus SOC Washington DC, USA November 2012.
  • Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358(11), 1129–1136 (2008).
  • Kesselheim JC, Norden AD, Wen PY, Joffe S. Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis. Oncologist 16(10), 1435–1439 (2011).
  • Najafi M, Soltanian-Zadeh H, Jafari-Khouzani K, Scarpace L, Mikkelsen T. Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI. PLoS One 7(1), e29945 (2012).
  • Clark AJ, Lamborn KR, Butowski NA et al. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery 70(2), 361–370 (2012).
  • Brandes AA, Tosoni A, Franceschi E et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J. Clin. Oncol. 27, 1275–1279 (2009).
  • Goldlust SA, Cavaliere R, Newton HB et al. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. J. Neurooncol. 107(2), 407–411 (2012).
  • Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin. Biol. Ther. 8, 541–553 (2008).
  • Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17, 2572–2578 (1999).
  • Ananthnarayan S, Bahng J, Roring J et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J. Neurooncol. 88(3), 339–347 (2008).
  • Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Curr. Neurol. Neurosci. Rep. 11(3), 305–312 (2011).
  • Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J. Clin. Oncol. 28(11), 1963–1972 (2010).
  • Greenfield JP, Jin DK, Young LM et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery 64(5), 819–826; discussion 826–827 (2009).
  • Schmidt NO, Westphal M, Hagel C et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer 84, 10–18 (1999).
  • Salmaggi A, Eoli M, Frigerio S et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J. Neurooncol. 62, 297–303 (2003).
  • Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin. Cancer Res. 9, 3369–3375 (2003).
  • Maity A, Pore N, Lee J, Solomon D, O’Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3´-kinase and distinct from that induced by hypoxia. Cancer Res. 60, 5879–5886 (2000).
  • Winkler F, Kozin SV, Tong R et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6, 553–563 (2004).
  • Gorski DH, Beckert MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374–3378 (1999).
  • Rosell R, de Las PR, Balana C et al. Translational research in glioblastoma multi-forme: molecular criteria for patient selection. Future Oncol. 4, 219–228 (2008).
  • Pore N, Liu S, Haas-Kogan DA, O’Rourke DM, Maity A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res. 63, 236–241 (2003).
  • Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817–2823 (2010).
  • Wen PY, Prados M, Schiff D et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients with progressive glioblastoma (GB). J. Clin. Oncol. 28(15 Suppl.), Abstract 2006 (2010).
  • Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168–1174 (2010).
  • Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 18(4), 708–715 (2000).
  • Marx GM, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 54(1), 31–38 (2001).
  • Kesari S, Schiff D, Henson JW et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncol. 10(3), 300–308 (2008).
  • Pan E, Yu D, Yue B et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J. Neurooncol. 110(1), 111–118 (2012).
  • Kreisl TN, Smith P, Sul J et al. Continuous daily sunitinib for recurrent glioblastoma. J. Neurooncol. 111(1), 41–48 (2013).
  • Lee EQ, Kuhn J, Lamborn KR et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncol. 14(12), 1511–1518 (2012).
  • de Groot JF, Lamborn KR, Chang SM et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 29(19), 2689–2695 (2011).
  • Drappatz J, Norden AD, Wong ET et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 78(1), 85–90 (2010).
  • Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA. A Phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro-Oncol. 14(12), 1519–1526 (2012).
  • Iwamoto FM, Lamborn KR, Robins HI et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncol. 12(8), 855–861 (2010).
  • Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J. Neurooncol. 111(2), 205–212 (2013).
  • Doi T, Ohtsu A, Fuse N et al. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 71(1), 227–235 (2013).
  • Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res. 72(5), 1103–1115 (2012).
  • Nakamura K, Taguchi E, Miura T et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 66(18), 9134–9142 (2006).
  • Hedgethorne K, Huang PH. Foretinib. c-Met and VEGFR-2 inhibitor, oncolytic. Drugs Fut. 35(11), 893–901 (2010).
  • Albert DH, Tapang P, Magoc TJ et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 5(4), 995–1006 (2006).
  • Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10(7), 505–514 (2010).
  • Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8(8), 604–617 (2008).
  • Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93(3), 178–193 (2001).
  • Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011–1027 (2005).
  • Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 8(8), 632–645 (2008).
  • Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039–2049 (2008).
  • Grothey A, Cutsem EV, Sobrero A et al.; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863), 303–312 (2013).
  • Idbaih A, Ducray F, Sierra DR, Hoang-Xuan K, Delattre JY. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist 13, 978–992 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.